Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging

PURPOSE: Mild breast cancer-related lymphedema (BCRL) is clinically diagnosed as a 5%–10% increase in arm volume, typically measured no earlier than 3–6 months after locoregional treatment. Early BCRL treatment is associated with better outcomes, yet amid increasing evidence that lymphedema exists i...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldrich, Melissa B., Rasmussen, John C., DeSnyder, Sarah M., Woodward, Wendy A., Chan, Wenyaw, Sevick-Muraca, Eva M., Mittendorf, Elizabeth A., Smith, Benjamin D., Stauder, Michael C., Strom, Eric A., Perkins, George H., Hoffman, Karen E., Mitchell, Melissa P., Barcenas, Carlos H., Isales, Lynn E., Shaitelman, Simona F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272652/
https://www.ncbi.nlm.nih.gov/pubmed/35816269
http://dx.doi.org/10.1007/s10549-022-06667-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272652/
https://www.ncbi.nlm.nih.gov/pubmed/35816269
http://dx.doi.org/10.1007/s10549-022-06667-4

Ejemplares similares